| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom;
Division of Ophthalmology, University of Bristol, Bristol, United Kingdom; and
DNAX Research, Inc., Palo Alto, CA 94304
A single exposure to inhaled Ag 10 days before immunization leads to long term, Ag-specific tolerance. Respiratory tract myeloid APCs are implicated, but how regulation is invoked, and how tolerance is sustained are unclear. This study examines the in vivo function of the myeloid regulatory molecule CD200 in the process of tolerance induction. Despite earlier onset of experimental autoimmune uveitis in sham-tolerized, CD200-deficient mice, disease incidence and subsequent severity were actually reduced compared with those in wild-type mice. Protection was more effective and long term, lasting at least 28 days. Halting disease progression and tolerance in CD200–/– mice correlated with a marked increase in Th2-associated cytokine production by Ag-challenged splenocytes. Reduced overall disease and enhanced tolerance in the CD200-deficient mice in this model system were unexpected and may be related to altered populations of MHC class IIlow APC in the respiratory tract compared with wild-type mice together with associated activation of STAT6 in draining lymph nodes of tolerized mice. These data indicate that in the absence of default inhibitory CD200 receptor signaling, alternative, powerful regulatory mechanisms are invoked. This may represent either permissive dominant Th2 activation or an altered hierarchy of negative signaling by other myeloid cell-expressed regulatory molecules.
This article has been cited by other articles:
|
|
 |
|
  D. A. Copland, C. J. Calder, B. J.E. Raveney, L. B. Nicholson, J. Phillips, H. Cherwinski, M. Jenmalm, J. D. Sedgwick, and A. D. Dick Monoclonal Antibody-Mediated CD200 Receptor Signaling Suppresses Macrophage Activation and Tissue Damage in Experimental Autoimmune Uveoretinitis Am. J. Pathol., August 1, 2007; 171(2): 580 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kretz-Rommel, F. Qin, N. Dakappagari, E. P. Ravey, J. McWhirter, D. Oltean, S. Frederickson, T. Maruyama, M. A. Wild, M.-J. Nolan, et al. CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy J. Immunol., May 1, 2007; 178(9): 5595 - 5605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, R. Dawson, J. V. Forrester, and J. Liversidge Identification of Novel Dendritic Cell Populations in Normal Mouse Retina Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1701 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Guyver, D. A. Copland, C. J. Calder, A. Sette, J. Sidney, A. D. Dick, and L. B. Nicholson Mapping Immune Responses to mRBP-3 1-16 Peptide with Altered Peptide Ligands Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2027 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-X. Zhang, S. Yu, D. Calida, Z. Zhao, B. Gran, M. Kamoun, and A. Rostami Loss of the Surface Antigen 3G11 Characterizes a Distinct Population of Anergic/Regulatory T Cells in Experimental Autoimmune Encephalomyelitis J. Immunol., March 15, 2006; 176(6): 3366 - 3373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hatherley, H. M. Cherwinski, M. Moshref, and A. N. Barclay Recombinant CD200 Protein Does Not Bind Activating Proteins Closely Related to CD200 Receptor J. Immunol., August 15, 2005; 175(4): 2469 - 2474. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
